USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Kabushiki Kaisha Dnaform

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, active 2016–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

8
Total patents granted
7
CPC technology areas
18.3
Avg claims per patent
-67%
5-year filing velocity

The verdict

Kabushiki holds 8 US patents across 7 technology areas, rank #32,197 of 50,000 tracked assignees.

#32,197
of 50,000 US assignees by volume
Top 67%
by Innovation Score (30.1/100)
18.3
avg claims per patent
-67%
filing velocity, last 5 yrs

Portfolio overview

Kabushiki Kaisha Dnaform has been granted 8 US utility patents between 2016 and 2022, placing Kabushiki Kaisha Dnaform at rank #32,197 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Kabushiki Kaisha Dnaform is one of the more focused assignees in the PatentsView dataset. By volume, Kabushiki sits between K-technology USA, Inc. (8 patents, rank #32,193) and Kairish Innotech Private Ltd. (8 patents, rank #32,201) - the closest US assignees by grant volume. The composite Innovation Score of 30.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 6 in the 2015–2019 window, a -67% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Kabushiki Kaisha Dnaform's 18.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Kabushiki Kaisha Dnaform against peers pursuing similar technology classes.

Who files at Kabushiki's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Kabushiki holds 8 patents at rank #32,197, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Kabushiki

By rank, the assignees closest to #32,197 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Kabushiki's primary technology class.

Kabushiki's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

30 Top 67% higher than 33% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#32,197

Across all tracked assignees

Innovation Score

30.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Kabushiki Kaisha Dnaform hold?
Kabushiki Kaisha Dnaform holds 8 US granted patents filed between 2016 and 2022, spanning 7 technology areas.
What is Kabushiki Kaisha Dnaform's Innovation Score?
Kabushiki Kaisha Dnaform has an Innovation Score of 30.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Kabushiki Kaisha Dnaform focus on?
Kabushiki Kaisha Dnaform's top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 8 patents. The company has filed patents in 7 CPC subclasses total.
Is Kabushiki Kaisha Dnaform's patent filing rate increasing or decreasing?
Kabushiki Kaisha Dnaform's recent filing velocity is -67% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Kabushiki Kaisha Dnaform's patents?
Kabushiki Kaisha Dnaform's patents average 18.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Kabushiki Kaisha Dnaform patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Kabushiki's 8 grants land it in the top 67% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Kabushiki ranks #32,197 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.